Low-molecular-weight heparin inhibits hypoxic pulmonary hypertension and vascular remodeling in guinea pigs

Chest

Volumn 132, Issue 6, 2007, Pages 1898-1905

  Al Ansari, Essam ^a   Du, Hong Kai ^a   Yu, Lunyin ^a   Ochoa, Cristhiaan D ^a   Garg, Hari G ^a   Quinn, Deborah A ^a   Hales, Charles A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dalteparin; Enoxaparin; Hypoxia; Low molecular weight heparin

Indexed keywords

ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PARNAPARIN; PROTEIN P27;

AMBIENT AIR; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL WALL; CARDIOVASCULAR MALFORMATION; CELL CULTURE; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; GROWTH INHIBITION; GUINEA PIG; HEART INDEX; HEMATOCRIT; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; PULMONARY VASCULAR REMODELING; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR RESISTANCE;

EID: 37549005172     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-0941     Document Type: Article

References (44)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351:1655-1665
2. Kourembanas S, Bernfield M. Hypoxia and endothelial-smooth muscle cell interactions in the lung. Am J Respir Cell Mol Biol 1994; 11:373-374
3. Peacock A. Pulmonary hypertension due to chronic hypoxia. BMJ 1990; 300:763
4. Tozzi CA, Poiani GJ, Harangozo AM, et al. Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact endothelium. J Clin Invest 1989; 84:1005-1012
5. Thompson BT, Hassoun PM, Kradin RL, et al. Acute and chronic hypoxic pulmonary hypertension in guinea pigs. J Appl Physiol 1989; 66:920-928
6. Bochnowicz S, Osborn RR, Hay DW, et al. Hypoxia-induced pulmonary hypertension in an optimized environment for the guinea pig. Lab Anim 1997; 31:347-356
7. Hassoun PM, Thompson BT, Steigman D, et al. Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig. Am Rev Respir Dis 1989; 139:763-768
8. Castellot JJ Jr, Hoover RL, Karnovsky MJ. Glomerular endothelial cells secrete a heparin like inhibitor and a peptide stimulator of mesangial cell proliferation. Am J Pathol 1986; 125:493-500
9. Thompson BT, Spence CR, Janssens SP, et al. Inhibition of hypoxic pulmonary hypertension by heparins of differing in vitro antiproliferative potency. Am J Respir Crit Care Med 1994; 149:1512-1517
10. Cindhuchao N, Quinn DA, Garg HG, et al. Heparin inhibits SMC growth in the presence of human and fetal bovine serum. Biochem Biophys Res Commun 2003; 302:84-88
11. Yu L, Quinn DA, Garg HG, et al. Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ Res 2005; 97:937-945
12. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Haemost 1999; 25(suppl 3):5-16
13. Darien BJ, Fareed J, Centgraf KS, et al. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 1998; 9:274-281
14. Fareed J, Jeske W, Hoppensteadt D, et al. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Haemost 1996; 22(suppl 1):77-91
15. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997; 77:317-322
16. Hunter C, Barer GR, Shaw JW, et al. Growth of the heart and lungs in hypoxic rodents: a model of human hypoxic disease. Clin Sci Mol Med 1974; 46:375-391
17. Fulton RM, Hutchinson EC, Jones AM. Ventricular weight in cardiac hypertrophy. Br Heart J 1952; 14:413-420
18. Reid LM. The pulmonary circulation: remodeling in growth and disease: the 1978 J. Burns Amberson lecture. Am Rev Respir Dis 1979; 119:531-546
19. Meyrick B, Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation: an ultrastructural study. Lab Invest 1978; 38:188-200
20. Dahlberg CG, Thompson BT, Joseph PM, et al. Differential effect of three commercial heparins on Na+/H+ exchange and growth of PASMC. Am J Physiol 1996; 270:L260-L265
21. Castellot JJ Jr, Addonizio ML, Rosenberg R, et al. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol 1981; 90:372-379
22. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265:625-626
23. Hoover RL, Rosenberg R, Haering W, et al. Inhibition of rat arterial smooth muscle cell proliferation by heparin: II. In vitro studies. Circ Res 1980; 47:578-583
24. Benitz WE, Kelley RT, Anderson CM, et al. Endothelial heparan sulfate proteoglycan: I. Inhibitory effects on smooth muscle cell proliferation. Am J Respir Cell Mol Biol 1990; 2:13-24
25. Castellot JJ Jr, Wong K, Herman B, et al. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985; 124:13-20
26. Castellot JJ Jr, Favreau LV, Karnovsky MJ, et al. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin: possible role of a platelet endoglycosidase. J Biol Chem 1982; 257:11256-11260
27. Hales CA, Kradin RL, Brandstetter RD, et al. Impairment of hypoxic pulmonary artery remodeling by heparin in mice. Am Rev Respir Dis 1983; 128:747-751
28. Garg HG, Roughley PJ, Hales CA. Proteoglycans in lung disease. In: Garg HG, Hales CA, eds. Heparin as a potential therapeutic agent to reverse vascular remodeling. New York, NY: Marcel Dekker, 2003; 377-398
29. Cindhuchao N, Quinn DA, Garg HG, et al. Heparin inhibits SMC growth in the presence of human and fetal bovine serum. Biochem Biophys Res Commun 2003; 302:84-88
30. Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: heparin; a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103:2994-3018
31. Gouin-Thibanlt I, Pautas E, Siguret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf 2005; 28:333-349
32. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79:1-17
33. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698
34. Janssens SP, Thompson BT, Spence CR, et al. Polycythemia and vascular remodeling in chronic hypoxic pulmonary hypertension in guinea pigs. J Appl Physiol 1991; 71:2218-2223
35. Khorana AA, Sahni A, Altland OD, et al. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23:2110-2115
36. Wong J, Wang N, Miller JW, et al. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 1994; 58:439-451
37. Joseph PA, Garg HG, Thompson BT, et al. Influence of molecular weight, protein core and charge of native heparin fractions on pulmonary artery smooth muscle cell proliferation. Biochem Biophys Res Commun 1997; 241:18-23
38. Wright TC Jr, Castellot JJ Jr, Petitou M, et al. Structural determinants of heparin's growth inhibitory activity: interdependence of oligosaccharide size and charge. J Biol Chem 1989; 264:1534-1542
39. Dietrich CP, Shinjo SK, Moraes FA, et al. Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine. Semin Thromb Haemost 1999; 25(suppl 3):43-50
40. Benitz WE, Bernfield M. Endothelial cell proteoglycans: possible mediators of vascular responses to injury. Am J Respir Cell Mol Biol 1990; 2:407-408
41. Tiozzo R, Cingi MR, Reggiani D, et al. Effect of the desulfation of heparin on its anticoagulant and anti-proliferative activity. Thromb Res 1993; 70:99-106
42. Fletcher JP, Ao PY, Hawthorne WJ. Antiproliferative effects of low molecular weight heparin. ANZ J Surg 2004; 74:793-796
43. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114:489S-510S
44. Fareed J, Hoppensteadt D, Jeske W, et al. Low molecular weight heparins: are they different? Can J Cardiol 1998; 14(suppl E):28E-34E